BMS caffeine study
This article was originally published in The Tan Sheet
Bristol Myers-Squibb requests teleconference with FDA in "near future" to discuss several questions generated by agency comments on firm's clinical study proposal for trial comparing effects of aspirin/acetaminophen/ caffeine in varying doses with acetaminophen 1,000 mg alone. Excedrin marketer submitted study protocol in July 2001; FDA responded in February that acetaminophen-only arm is unnecessary, trial should include second pain model other than headache (1"The Tan Sheet" Feb. 25, 2002, p. 9). In May 31 submission, BMS maintains "we believe that many of the issues raised [by FDA] will be answered by providing the agency with a full protocol, rather than the protocol outline we submitted" in July. Complete protocol will be submitted after the teleconference, firm says...
You may also be interested in...
An acetaminophen-only treatment arm in Bristol-Myers Squibb's planned clinical study on the efficacy of different caffeine doses in analgesic adjuvancy is unnecessary, FDA says in a recent letter
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.